4Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015,65:87-108.
5Heidenreich A, Bastian PJ, BeUmuntJ, et al. EAU guidelines on prostate cancer, part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014,65:124-37.
6Merola R, Tomao L, Antenucci A, et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high- risk patients: a National Cancer Institute experience. J Exp Clin Cancer Res 2015,34:15.
7Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ ml: systematic review and recta-analysis. Eur Urol 2005,48:386-99, discussion 398-9.
8Jung M, Xu C, SpethmannJ, et al. Re: Hessels D, Klein GunnewiekJMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Sehalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Uro12003,44:8- 16. Eur Urol 2004,46:271-2.
9Tom[ins SA. Urine PCA3 and TMPRSS2:ERG using cancer-specific markers to detect cancer. Eur Urol 2014,65:543-5.
10Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007, 13:5103-8.
